-+ 0.00%
-+ 0.00%
-+ 0.00%

RBC Capital Maintains Outperform on Jazz Pharmaceuticals, Raises Price Target to $305

Benzinga·11/03/2026 15:01:31
Listen to the news
RBC Capital analyst Leonid Timashev maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Outperform and raises the price target from $296 to $305.